As the Australian stock market navigates the close of a turbulent financial year, it reflects a global trend of cautious optimism bolstered by strong performances in U.S. markets. Penny stocks, though often considered a relic from past market eras, continue to offer intriguing investment opportunities by highlighting smaller or newer companies that may be overlooked. By focusing on those with robust financials and potential for growth, investors can uncover promising prospects among these lesser-known equities.
Name |
Share Price |
Market Cap |
Financial Health Rating |
Alfabs Australia (ASX:AAL) |
A$0.37 |
A$106.04M |
★★★★☆☆ |
EZZ Life Science Holdings (ASX:EZZ) |
A$2.30 |
A$108.5M |
★★★★★★ |
GTN (ASX:GTN) |
A$0.65 |
A$123.97M |
★★★★★★ |
IVE Group (ASX:IGL) |
A$2.85 |
A$439.42M |
★★★★★☆ |
Southern Cross Electrical Engineering (ASX:SXE) |
A$1.79 |
A$473.29M |
★★★★★★ |
Sugar Terminals (NSX:SUG) |
A$0.99 |
A$352.8M |
★★★★★★ |
Navigator Global Investments (ASX:NGI) |
A$1.70 |
A$833.14M |
★★★★★☆ |
Lindsay Australia (ASX:LAU) |
A$0.72 |
A$228.41M |
★★★★☆☆ |
Bisalloy Steel Group (ASX:BIS) |
A$3.77 |
A$178.89M |
★★★★★★ |
CTI Logistics (ASX:CLX) |
A$1.775 |
A$142.97M |
★★★★☆☆ |
Click here to see the full list of 473 stocks from our ASX Penny Stocks screener.
Let’s take a closer look at a couple of our picks from the screened companies.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Aroa Biosurgery Limited is a company that develops, manufactures, and sells medical devices for wound and soft tissue repair using ECM technology, with a market cap of A$193.22 million.
Operations: The company generates revenue of NZ$84.70 million from its operations in developing, manufacturing, and selling soft tissue repair products.
Market Cap: A$193.22M
Aroa Biosurgery Limited, with a market cap of A$193.22 million, has shown promising growth in revenue, reporting NZ$84.70 million for the fiscal year ending March 31, 2025. Despite being currently unprofitable, it has reduced losses by 21.2% annually over five years and expects sales between US$90 million to US$100 million in Fiscal Year 2026. The company is debt-free and maintains a strong cash runway exceeding three years based on current free cash flow. Recent clinical studies highlight the effectiveness of its Endoform Natural product, potentially enhancing patient outcomes and reducing healthcare costs significantly.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: COSOL Limited, with a market cap of A$115.56 million, provides information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and other international markets.